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Propriedades antioxidante e anticancerígena foram relatadas para o Eugenol (4-alil-2-
metoxifenol) (1). Na tentativa de aumentar a atividade intrínseca deste composto natural, alguns 
derivados foram sintetizados. O eugenol foi extraído do óleo de cravo da Índia e seus análogos 
(2-6) foram obtidos por reações de acetilação e nitração. Eugenol (1) e seus análogos (2-6) foram 
avaliados in vitro frente a duas linhagens de células de câncer humanas: DU-145 (células de câncer 
de próstata, insensíveis a andrógeno) e KB (células de carcinoma escamoso oral). A viabilidade 
celular foi avaliada por ensaios com sal de tetrazólio. A liberação de desidrogenase lática (LDH) 
também foi investigada para avaliar a toxicidade celular como um resultado do rompimento celular 
subseqüente à ruptura da membrana. Todos os compostos apresentaram atividade inibitória sobre 
o crescimento das células cancerosas examinadas. Os resultados obtidos demonstram que os 
compostos 5-alil-3-nitrobenzeno-1,2-diol (3) e acetato de 4-alil-2-metoxi-5-nitrofenol (5) foram 
significativamente mais ativos que o eugenol (p < 0,001), com valores de IC50 em células DU-145 
de 19,02 × 10-6 e 21,5 × 10-6 mol L-1 respectivamente, sugerindo que a presença dos grupos nitro e 
hidroxila podem ser importantes na atividade destes compostos. Os resultados também parecem 
indicar que a morte por apoptose está sendo induzida em células KB e DU-145. Nas condições 
experimentais avaliadas, não foi observado qualquer aumento estatisticamente significativo na 
liberação de LDH pelas células de câncer quando tratadas com eugenol e seus análogos.
Eugenol (4-allyl-2-methoxyphenol) (1) has been reported to possess antioxidant and anticancer 
properties. In an attempt to enhance intrinsic activity of this natural compound, some derivatives 
were synthesized. Eugenol was extracted from cloves oil and further, the eugenol analogues (2-6)
were obtained through acetylation and nitration reactions. Eugenol (1) and its analogues (2-6)
were examined by in vitro model of cancer using two human cancer cell lines: DU-145 (androgen-
insensitive prostate cancer cells) and KB (oral squamous carcinoma cells). Cell viability, by 
tetrazolium salts assay, was measured. Lactic dehydrogenase (LDH) release was also investigated 
to evaluate the presence of cell toxicity as a result of cell disruption, subsequent to membrane 
rupture. In the examined cancer cells, all compounds showed cell-growth inhibition activity. The 
obtained results demonstrate that the compounds 5-allyl-3-nitrobenzene-1,2-diol (3) and 4-allyl-
2-methoxy-5-nitrophenyl acetate (5) were significantly (p < 0,001) more active than eugenol, with 
IC50 values in DU-145 cells of 19.02 x 10-6 and 21.5 × 10-6 mol L-1, respectively, and in KB cells 
of 18.11 × 10-6 and 21.26 × 10-6 mol L-1, respectively, suggesting that the presence of nitro and 
hydroxyl groups could be important in the activity of these compounds. In addition, our results 
seem to indicate that apoptotic cell demise appears to be induced in KB and DU-145 cells. In fact, 
in our experimental conditions, no statistically significant increase in LDH release was observed 
in cancer cells treated with eugenol and its analogues. 
Keywords: eugenol, synthesis, DU-145 cancer cells, KB cancer cells, cell viability, lactic 
dehydrogenase (LDH) release
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Introduction
Eugenol (4-Allyl-2-methoxyphenol) (Scheme 1),
a main constituent of the essential oil obtained from 
commonly consumed spices such as Pimenta racemosa 
(bay leaves), Cinnamomum verum (cinnamon leaf) and
Syzygium aromaticum (clove), is used as antiseptic, 
antibacterial, analgesic agent in traditional medical 
practices.1 Now, it is used in pharmaceutical and food 
products and in beverages as a flavoring agent.2 The 
therapeutic benefits of eugenol are well known. In recent 
times, it has been studied for a variety of promising 
biological properties. It has been reported to participate 
in photochemical reactions and to possess insecticidal, 
antioxidant and anti-inflammatory activities.3,4,5
Eugenol has been demonstrated to inhibit prostaglandin 
biosynthesis and to block COX-2 activity (1). It is 
important that in several studies, this natural compound 
was reported to be non genotoxic and non carcinogenic. In 
long term carcinogenicity experiments by various groups 
in CD-1 mice and F344 rats, eugenol was not associated 
with tumor formation.1 In addition, it was found to be 
protective against many genotoxins and carcinogens, 
biochemical studies in mice and rats have demonstrated 
its role as an effective inducer of detoxifying phase 
II enzymes.2 Recently, an anticancer activity was 
hypothesized. Preclinic studies have demonstrated that 
eugenol induces a reactive oxygen species-mediated 
apoptosis in HL-60 human promyelocytic leukemia 
cells and causes melanoma growth suppression through 
inhibition of E2F1 transcriptional activity.6,1 In view of 
these experimental evidences on anti-tumor properties 
of eugenol, to enhance intrinsic activity of this natural 
compound. In the present work, five derivatives were 
synthesized and the prepared compounds were tested 
for cell-growth inhibition activity towards DU-145 
(androgen-insensitive prostate cancer cells) and KB (oral 
squamous carcinoma cells) human tumor cell lines. 
Experimental
General
Unless otherwise stated, all chemical reagents were 
purchased with the highest commercially available purity 
(Merck or Aldrich) and were used without previous 
purification. Melting points were measured on a Stuart-
Scientific SMP3 apparatus and are uncorrected. IR spectra 
were recorded as thin film or KBr pellets in a Nicolet Impact 
420 spectrometer. N
max
 values are expressed in cm-1. 1H
and 13C NMR spectra were recorded in CDCl3 solutions 
and referenced to the residual peak of CHCl3 at G 7.26 
ppm and G 77.00 ppm for 1H and 13C, respectively, on a 
Bruker Avance 400 Digital NMR spectrometer, operating 
at 400.1 MHz for 1H and 100.6 MHz for 13C. Chemical 
shifts are reported in G ppm and coupling constants (J)
are given in Hz. HRMS were recorded on a MAT 95XP, 
Thermo Finnigan spectrometer and represented as m/z
(% rel. int.). Silica gel (Merck 200-300 mesh) was used 
for CC and silica gel plates and HF-254 for TLC. Spots 
were detected on TLC by heating after spraying with 25% 
H2SO4 in H2O.
Synthesis
Eugenol (1) was obtained from cloves essence, according 
to standard procedure.10 Previously our investigation 
group reported the synthesis, spectroscopic analysis and 
crystalline structure of compound 5.11 Isoeugenol (6) was 
obtained by isomerization from eugenol according to 
the procedure previously described with modifications, 
extending the reaction time to 5 hours. Eugenol (1) and its 
analogues (2-6) are showed in Scheme 1.12
4-Allyl-2-methoxy-6-nitrophenol (2) and 5-allyl-3-
nitrobenzene-1,2-diol (3): Eugenol 1.5 g (9.15 mmol) was 
dissolved in dichloromethane (30 mL) and was added to 
a mixture which contained 4.5 g (33 mmol) of potassium 
hydrogen sulphate, 3.0 g (35.3 mmol) of sodium nitrate and 
3.5 g of wet silica to 50% P/P; the mixture was left with 
constant stirring at room temperature for 5.5 hours. The 
complete disappearance of the starting product was confirmed 
by thin layer chromatography (TLC) (AcOEt:n-hexane 1:3). 
The reacted mixture was filtered through silica and the 
solid was washed with dichloromethane, and the solvent 
evaporated in vacuum to give a reddish oil. Pure product 
was obtained after chromatografic column (5:1 – 3:1 AcOEt 
in hexane), which gave 1.10 g of the desired compound 2
(63.2% yield) and 0.043 g (2.9%) of 3. Compound 2 (oil):
IR (film) N
max
/cm-1: 3232 (O-H), 3084 (C=CH-Ar), 3014 
(CH=CH2), 2936, 2829, 1634 (C=C), 1547 (NO2), 1399, Scheme 1. Synthesis of eugenol derivatives. 
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1327, 1260 (C-O), 1127 (C-O), 1066, 999, 912, 764. 
1H NMR (400.1 MHz, CDCl3): G 3.35 (2H, d, J 6.6 Hz, 
H1’); 3.93 (3H, s, OCH3); 5.13 (2H, m, H3’); 5.91 (1H, m, 
H2’); 6.96 (1H, s, H3); 7.50 (1H, d, J 0.9 Hz, H5); 10.67 
(1H, s, OH). 13C NMR (100.6 MHz, CDCl3): G 39.4 (C1’); 
56.7 (OCH3); 115.1 (C5); 117.1 (C3’); 118.6 (C3); 131.2 
(C4); 133.6 (C6); 135.9 (C2’); 144.9 (C1); 149.8 (C2). 
HRMS (EI): m/z calcd. for C10H11NO4 [M]+ 209.03 (100%): 
209.06881, found 209.06921. Compound 3 (yellow oil): IR
(film) N
max
/cm-1: 3471 (O-H), 3386 (O-H), 3079 (C=CH-
Ar), 3018 (CH=CH2), 2971, 2929, 2850, 1639 (C=C), 1542 
(NO2), 1460, 1342, 1276 (C-O), 1235, 1117, 1025 (C-O). 
1H NMR (400.1 MHz, CDCl3): G 3.32 (2H, d, J 6.5 Hz, 
H1’); 5.19 (2H, m, H3’); 5.90 (2H, m, H2’ and OH); 7.09 
(1H, d, J 1.9 Hz, H6); 7.46 (1H, d, J; 1.8 Hz, H4); 10.5 
(1H, s, OH). 13C NMR (100.6 MHz, CDCl3): G 39.1 (C1’); 
115.0 (C4); 117.1 (C3’); 122.3 (C6); 132.2 (C3); 133.4 
(C5); 135.8 (C2’); 141.3 (C2); 146.3 (C1). HRMS (EI): 
m/z calcd. for C9H9NO4 [M]+ 195.03 (80.6%): 195.05316, 
found 195.5241.
4-Allyl-2-methoxyphenyl acetate (4): To a stirred 
solution of eugenol 10.00 g (6.10 mmol) in pyridine (2.00 
mL) was added dichloromethane (20 mL) and 10 mg of 
4-N,N-dimethylaminopyridine (DMAP). The solution was 
stirred at room temperature for 30 min. Acetic anhydride 
was added and the reaction was left to continue for 1 h and 
after this period, the complete disappearance of the starting 
product was confirmed by thin layer chromatography 
(TLC) (AcOEt:n-hexane 1:3). To the stopped reaction a 
10% solution of potassium hydrogen sulphate was added 
and extracted with dichloromethane. The organic phase 
was washed with water (3 x 20 mL) until pH 7, dried with 
anhydrous Na2SO4 and vacuum evaporated. Pure product 
was obtained by column chromatography (5:1 – 3:1 
AcOEt in hexane), which gave the desired compound with 
quantitative yield. Compound 4 (oil): IR (film) N
max
/cm-1:
3078 (C=CH-Ar), 3011 (CH=CH2), 2971, 2935, 2843, 
1762 (C=O), 1634 (C=C), 1603, 1501, 1465, 1373, 1265 
(C-O), 1200, 1143 (C-O), 1030, 917. 1H NMR (400.1 MHz, 
CDCl3): G 2.31 (3H, s, CH3CO2); 3.38 (2H, d, J 6.7 Hz, 
H1’); 3.82 (3H, s, OCH3); 5.10 (2H, m, H3’); 5.97 (1H, 
m, H2’); 6.77 (2H, m, H3 and H5); 6.95 (1H, d, J 7.9 Hz, 
H6). 13C NMR (100.6 MHz, CDCl3): G 20.6 (CH3CO2); 40.1 
(C1’); 55.8 (OCH3); 112.7 (C3); 116.1 (C3’); 120.6 (C5); 
122.5 (C6); 137.0 (C4); 138.0 (C1); 139.0 (C2’); 150.8 
(C2); 169.2 (CH3CO2).
4-Allyl-2-methoxy-3-nitrophenyl acetate (5): To 
a stirred solution of 4-allyl-2-methoxyphenyl acetate 
200 mg (0.97 mmol) in dichloromethane (5 mL) was 
carefully added at 0 °C 2 mL of a sulphonitric mixture, 
which was prepared by adding concentrated nitric acid 
on concentrated sulphuric acid. The reaction was left to 
continue for 30 minutes and after this period, the complete 
disappearance of the starting product was confirmed by 
thin layer chromatography (TLC) (AcOEt:n-hexane 1:3). 
The reaction was interrupted by adding 15 mL water. The 
organic layer was washed with water (3 x 20 mL) in order to 
extract the excess of acid present and dried with anhydrous 
Na2SO4, filtered, and the solvent was evaporated at low 
pressure obtaining an oily product, which was purified 
by flash chromatography (AcOEt:n-hexane) which 
allowed obtaining 89 mg (35%) of the mixture of isomers.
The mixture of isomers was, then, re-crystallized from 
AcOEt/n-hexane mixture. Compound 5 (brown-yellow 
crystal) 145-147 °C: IR (KBr) N
max
/cm-1: 3079 (C=CH-Ar), 
3021 (CH=CH2), 2979, 2914, 2836, 1778 (C=O), 1614 
(C=C), 1527 (NO2), 1440, 1332, 1276 (C-O), 1199 (C-O), 
1173, 1050, 922. 1H NMR (400.1 MHz, CDCl3): G 2.32 
(3H, s, CH3CO2); 3.76 (2H, d, J 6.4 Hz, H1’); 3.91(3H, s, 
OCH3); 5.14 (2H, m, H3’); 5.98 (1H, m, H2’); 6.85 (1H, 
s, H6); 7.83 (1H, s, H3). 13C NMR (100.6 MHz, CDCl3): 
G 20.4 (CH3CO2); 37.7 (C1’); 56.3 (OCH3); 114.2 (C6); 
117.4 (C3’); 120.7 (C3); 134.8 (C4); 136.1 (C2’); 137.7 
(C5); 140.9 (C1); 155.1 (C2); 168.4 (CH3CO2). HRMS 
(EI): m/z calcd. for C12H13NO5 [M]+ 251.05 (9.2%): 
251.07937, found 251.07273.
(E)-2-Methoxy-4-(prop-1-enyl) phenol (isoeugenol 6): 
To 8.0 g of ethyleneglicol placed in a three-neck round-
bottom flask of 100 mL are added 7.90 g of KOH (134 
mmol), and submerged in a sand bath. To the mixture 
eugenol 5.0 g (30.5 mmol) is added and the system is 
refluxed at 160 °C for about approximately 5 hours; at 
this time the reaction is stopped. The excess of KOH 
is neutralized with 25 mL of a 6 mol L-1 hydrochloric 
acid solution, the mixture is extracted with CHCl3
(2 × 50 mL) and the organic phase is dried with anhydrous 
Na2SO4 and the solvent evaporated under vacuum. After 
chromatographic column purification, 4.25 g of a brown 
oil was obtained (85%). IR (film) N
max
/cm-1: 3503 (O-H), 
3057 (C=CH-Ar), 3014 (CH=CH), 2936, 2930, 2843, 1603, 
1506, 1367, 1030, 963. 1H NMR (400.1 MHz, CDCl3): G
1.86 (3H, dd, J 1.5 and 6.6 Hz, CH3); 3.90 (3H, s, OCH3);
5.55 (1H, s, OH); 6.08 (1H, dq, J 6.6 and 15.7 Hz, H2’); 
6.32 (1H, dd, J 1.5 and 15.7 Hz, H1’); 6.85 (3H, m, H3, H5 
and H6). 13C NMR (100.6 MHz, CDCl3): G 18.3 (CH3); 55.8 
(OCH3); 107.8 (C5); 114.3 (C6); 119.3 (C3); 123.4 (C4); 
130.6 (C2); 130.7 (C1); 144.7 (C2’); 146.5 (C1’).
Biological
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) and reduced nicotinamide adenine 
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dinucleotide (NADH) were obtained from Sigma Aldrich 
Co (St. Louis, USA). All other chemicals were purchased 
from GIBCO BRL Life Technologies (Grand Island, NY, 
USA).
Study on human tumor cell lines
Cell culture and treatments
The experimental cell cultures were obtained from 
American Type Culture Collection (Rockville, MD, USA). 
DU-145 cells (androgen-insensitive prostate cancer cells) 
were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% FCS, 100 U mL-1 penicillin, 
100 µg mL-1 streptomycin, 1 mM glutamine, and 1% non 
essential amino-acids. KB cells (oral squamous carcinoma 
cells) were maintained in RPMI supplemented with 10% 
fetal calf serum (FCS), 100 U ml-1 penicillin, and 100 µg 
mL-1 streptomycin. After 24 h incubation at 37 °C under a 
humidified 5% carbon dioxide to allow cell attachment, the 
cells were treated with different concentrations of eugenol 
(1) and its synthetic analogues (2-6) and incubated for 72 h
under the same conditions. Stock solution of compounds 
were prepared in DMSO and the final concentration of 
this solvent was kept constant at 0.25%. Control cultures 
received DMSO alone. 
MTT bioassay 
MTT assay was performed as previously described.13
Briefly, the cells were set up 6 x 103 cells per well of a 
96-well, flat-bottomed 200 µL microplate. Cells were 
incubated at 37 °C in a humidified 5% CO2/95% air mixture 
and treated with doxorubicin, used as a positive control, and 
the compounds (1-6) at different concentrations for 72 hours. 
Four hours before the end of the treatment time, 20 µL of 
0.5% 3-(4, 5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) in phosphate buffer saline (PBS) were added 
to each microwell. Cells were washed once before adding 
MTT. After 4 h of incubation at 37 °C, the supernatant was 
removed and replaced with 100 µL of DMSO. The optical 
density of each well sample was measured with a microplate 
spectrophotometer reader (Digital and Analog Systems, 
Rome, Italy) at L = 550 nm.
Lactic dehydrogenase (LDH) release
Lactic dehydrogenase (LDH) activity was spectro-
photometrically measured in the culture medium and in 
the cellular lysates at L = 340 nm by analyzing NADH 
reduction during the pyruvate-lactate transformation, as 
previously reported.14 Cells were lysed with 50 mmol L-1
Tris-HCl + 20 mmol L-1 EDTA pH 7.4 + 0.5% sodium 
dodecyl sulfate (SDS), further disrupted by sonication and 
centrifuged at 13.000 g for 15 min. The assay mixture (1 mL 
final volume) for the enzymatic analysis contained: 33 ML
of sample (5-10 Mg of protein) in 48 mmol L-1 PBS pH 7.5 
plus 1 mmol L-1 pyruvate and 0.2 mmol L-1 NADH. The 
percentage of LDH released was calculated as percentage 
of the total amount, considered as the sum of the enzymatic 
activity present in the cellular lysate and that in the culture 
medium. A Hitachi U-2000 spectrophotometer (Hitachi, 
Tokyo, Japan) was used.
Statistical Analysis
Statistical analysis of results was performed by using 
one-way ANOVA followed by Dunnett’s post-hoc test for 
multiple comparisons with control. All statistical analyses 
were performed using the statistical software package 
SYSTAT, version 9 (Systat Inc., Evanston IL, USA).
We included after the reference section some supplementary 
information. This incorporated the 1D and 2DNMR, HRMS 
and IR spectra. Finally we indicated the solvent utilized in each 
case and all relevant information for these compounds.
Results and Discussion
Cancer is the largest single cause of death in both men 
and women. Recently, resistance to anticancer drugs has 
been observed. Therefore, the research and development of 
more effective and less toxic drugs by the pharmaceutical 
industry has become necessary. Many substances derived 
from dietary or medicinal plants are known to be effective 
and versatile chemopreventive and antitumoral agents in a 
number of experimental models of carcinogenesis. There 
is increasing evidence for an association between a high 
consumption of fruit and vegetables and the reduced risk 
of oral cancer and prostate carcinoma, the most common 
tumor in men.7,8 Since antiproliferative screening models in 
vitro provide important preliminary data to help selecting 
compounds with potential antineoplastic properties for 
future study, eugenol (1) and its analogues (2-6) were 
tested in vitro for their potential human tumor cell growth 
inhibitory effect on DU-145 and KB tumor cell lines using 
MTT assay, a non-radioactive, fast and economical assay 
widely used to quantify cell viability and proliferation. MTT 
is a yellow water-soluble tetrazolium salt. Metabolically
active cells are able to convert the dye to water-insoluble 
dark blue formazan by reductive cleavage of the tetrazolium 
ring. The results, summarized in Table 1, show that eugenol 
(1) and its analogues (2-6) exhibited a inhibitory effect on 
both the human cancer cells examined, with IC50 value 
lower than of 50 x 10-6 mol L-1. The compounds 2, 4 and 6
showed cell growth inhibition activity comparable to that 
of eugenol, while the compounds 5-allyl-3-nitrobenzene-
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1,2-diol (3) and 4-allyl-2-methoxy-5-nitrophenyl acetate 
(5) were significantly (p < 0,001) more active than eugenol, 
with IC50 value in DU-145 cells of 19.02 × 10-6 mol L-1 and 
21.5 × 10-6 mol L-1, respectively, and in KB cells of 18.11 
× 10-6 mol L-1 and 21.26 × 10-6 mol L-1, respectively. The 
reason for this increased potency with nitration reaction 
may be due to increased lipophilicity which allows more 
compound to cross the plasma membrane of the cell. Also 
the position of nitro group could play a key role, in fact 
the 4-allyl-2-methoxy-5-nitrophenyl acetate (5) was more 
active than 4-allyl-2-methoxy-6-nitrophenol (2). It has been 
suggested that available hydroxyl groups are important 
for decreasing cancer cell viability.9 Our results seem to 
agree to this hypothesis, in fact the compound 5-allyl-3-
nitrobenzene-1,2-diol (3) was significantly more potent 
than eugenol (1).
Necrosis results in a disruption of cytoplasmic 
membrane and the necrotic cells release cytoplasmic 
LDH and other cytotoxic substances into the medium. 
We therefore examined the membrane permeability of the 
treated cells through the existence of LDH in their culture 
medium. Our results seem to suggest that apoptotic cell 
demise appears to be induced in KB and DU-145 cells. In 
fact, no statistically significant increase in LDH release was 
observed in our experimental conditions (Table 2).
Conclusion
In summary, these results are starting point for further 
investigations, seem to indicate that a apoptotic process 
could be activated by eugenol and its analogues in our 
experimental conditions, and that the presence of nitro 
and hydroxyl groups could be positively correlated with 
the potency of 5-allyl-3-nitrobenzene-1,2-diol (3) and 
4-allyl-2-methoxy-5-nitrophenyl acetate (5) compounds,
suggesting that these nitro-derivatives may have a 
chemotherapeutic role in the future.
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Table 1. Cell growth inhibition, assayed using MTT test, of DU-145 and 
KB cells untreated and treated with eugenol (1) and its analogues (2-6) at 
different concentrations for 72 hours. Stock solution of compounds was 
prepared in DMSO and the final concentration of this solvent was kept 
constant at 0.25%. Control cultures received DMSO alone
Treatments DU-145 cells IC50 (mol L-1)a KB cells
1 30.39 × 10-6 28.48 × 10-6
2 34.98 × 10-6 33.97 × 10-6
3 19.02 × 10-6* 18.11 × 10-6*
4 29.26 × 10-6 29.68 × 10-6
5 21.50 × 10-6* 21.26 × 10-6*
6 30.71 × 10-6 27.50 × 10-6
Dox 9.28 × 10-6 1.35 × 10-6
aResults are expressed as IC50 values (mol L-1). The IC50 value, relative to 
untreated control, represents the concentration that inhibited cell viability 
by 50%. Doxorubicin (Dox) was used as a positive control. Values are 
the mean o SD of three experiments performed in triplicate. *significant
vs. eugenol (1) treated cells (p < 0.001).
Table 2. Lactate dehydrogenase (LDH) release) in DU-145 and KB cells 
untreated and treated with eugenol (1) and its analogues (2-6) at different 
concentrations for 72 hours. Stock solution of compounds was prepared 
in DMSO and the final concentration of this solvent was kept constant at 
0.25%. Control cultures received DMSO alone.
Treatments DU-145  cells % LDH released KB cells
Control 2.9 ± 0.7 4.9 ± 0.6
1
12 × 10-6 mol L-1 3.1 ± 0.1 3.6 ± 0.4
25 × 10-6 mol L-1 4.3 ± 0.9 4.3 ± 0.6
50 × 10-6 mol L-1 3.5 ± 0.3 2.9 ± 0.9
2
12 × 10-6 mol L-1 3.3 ± 0.9 4.5 ± 0.8
25 × 10-6 mol L-1 4.3 ± 0.8 3.7 ± 0.4
50 × 10-6 mol L-1 3.8 ± 0.9 2.9 ± 0.3
3
12 × 10-6 mol L-1 4.6 ± 0.7 4.5 ± 0.6
25 × 10-6 mol L-1 3.4 ± 0.9 2.4 ± 0.9
50 × 10-6 mol L-1 2.8 ± 0.9 4.4 ± 0.9
4
12 × 10-6 mol L-1 2.6 ± 0.7 3.9 ± 0.5
25 × 10-6 mol L-1 3.1 ± 0.9 2.7 ± 0.8
50 × 10-6 mol L-1 2.9 ± 0.3 3.4 ± 0.2
5
12 × 10-6 mol L-1 3.7 ± 0.5 4.0 ± 0.5
25 × 10-6 mol L-1 4.4 ± 0,9 3.7 ± 0,6
50 × 10-6 mol L-1 3.9 ± 0.3 2.4 ± 0.9
6
12 × 10-6 mol L-1 3.7 ± 0.5 3.9 ± 0.8
25 × 10-6 mol L-1 3.0 ± 0.9 3.5 ± 0.6
50 × 10-6 mol L-1 3.9 ± 0.2 3.6 ± 0.5
The results are expressed as percentage of LDH released into the cell 
medium with respect to total LDH. Each value represents the mean ± 
SD of three experiments, performed in triplicate.
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4-Allyl-2- methoxy-6-nitrophenol: In the pages S2-S4 
we indicated the 1D & 2D NMR, HRMS, and IR spectra. 
IR spectra were recorded as thin film or KBr pellets in a 
Nicolet Impact 420 spectrometer. N
max
 values are expressed 
in cm-1. 1H and 13C NMR spectra were recorded in CDCl
3
solutions and referenced to the residual peak of CHCl
3
 at D
7.26 ppm and D 77.00 ppm for 1H and 13C, respectively, on 
a Bruker Avance 400 Digital NMR spectrometer, operating 
at 400.1 MHz for 1H and 100.6 MHz for 13C. Chemical 
shifts are reported in D ppm and coupling constants (J)
are given in Hz. HRMS were recorder on a MAT 95XP, 
Thermo Finnigan spectrometer and represented at m/z
(% rel. int.).
5-Allyl-3-nitrobenzene-1,2-diol: In the pages S5-S7 
we indicated the 1D & 2D NMR, HRMS, and IR spectra. 
IR spectra were recorded as thin film or KBr pellets in a 
Nicolet Impact 420 spectrometer. N
max
 values are expressed 
in cm-1. 1H and 13C NMR spectra were recorded in CDCl
3
solutions and referenced to the residual peak of CHCl
3
 at D
7.26 ppm and D 77.00 ppm for 1H and 13C, respectively, on 
a Bruker Avance 400 Digital NMR spectrometer, operating 
at 400.1 MHz for 1H and 100.6 MHz for 13C. Chemical 
shifts are reported in D ppm and coupling constants (J)
are given in Hz. HRMS were recorder on a MAT 95XP, 
Thermo Finnigan spectrometer and represented at m/z 
(% rel. int.).
4-Allyl-2-methoxyphenyl acetate: In the pages S8-S9 
we indicated the 1D & 2D NMR, HRMS, and IR spectra. 
IR spectra were recorded as thin film or KBr pellets in a 
Nicolet Impact 420 spectrometer. N
max
 values are expressed 
in cm-1. 1H and 13C NMR spectra were recorded in CDCl
3
solutions and referenced to the residual peak of CHCl
3
 at D
7.26 ppm and D 77.00 ppm for 1H and 13C, respectively, on 
a Bruker Avance 400 Digital NMR spectrometer, operating 
at 400.1 MHz for 1H and 100.6 MHz for 13C. Chemical 
shifts are reported in D ppm and coupling constants (J)
are given in Hz. HRMS were recorder on a MAT 95XP, 
Thermo Finnigan spectrometer and represented at m/z
(% rel. int.).
4-Allyl-2-methoxy-5-nitrophenyl acetate: In the pages 
S10-S11 we indicated the 1D & 2D NMR, HRMS, and 
IR spectra. IR spectra were recorded as thin film or 
KBr pellets in a Nicolet Impact 420 spectrometer. N
max
values are expressed in cm-1. 1H and 13C NMR spectra 
were recorded in CDCl
3
 solutions and referenced to the 
residual peak of CHCl
3
 at D 7.26 ppm and D 77.00 ppm for 
1H and 13C, respectively, on a Bruker Avance 400 Digital 
NMR spectrometer, operating at 400.1 MHz for 1H and 
100.6 MHz for 13C. Chemical shifts are reported in D ppm 
and coupling constants (J) are given in Hz. HRMS were 
recorder on a MAT 95XP, Thermo Finnigan spectrometer 
and represented at m/z (% rel. int.).
(E)-2-Methoxy-4-(prop-1-enyl) phenol: In the pages 
S12-S13 we indicated the 1D & 2D NMR, HRMS, and 
IR spectra. IR spectra were recorded as thin film or 
KBr pellets in a Nicolet Impact 420 spectrometer. N
max
values are expressed in cm-1. 1H and 13C NMR spectra 
were recorded in CDCl
3
 solutions and referenced to the 
Eugenol and its Synthetic Analogues Inhibit Cell Growth of Human Cancer Cells (Part I) J. Braz. Chem. Soc.S2
residual peak of CHCl
3
 at D 7.26 ppm and D 77.00 ppm for 
1H and 13C, respectively, on a Bruker Avance 400 Digital 
NMR spectrometer, operating at 400.1 MHz for 1H and 
100.6 MHz for 13C. Chemical shifts are reported in D ppm 
and coupling constants (J) are given in Hz. HRMS were 
recorder on a MAT 95XP, Thermo Finnigan spectrometer 
and represented at m/z (% rel. int.).
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